Oramed Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of March 2026: 19.58%

Oramed Pharmaceuticals Inc (ORMP) has an Asset Resilience Ratio of 19.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Oramed Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$52.64 Million

Cash + Short-term Investments

Total Assets

$268.85 Million

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how Oramed Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ORMP current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Oramed Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Oramed Pharmaceuticals Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$52.64 Million	19.58%
Total Liquid Assets	$52.64 Million	19.58%

Asset Resilience Insights

Good Liquidity Position: Oramed Pharmaceuticals Inc maintains a healthy 19.58% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Oramed Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Oramed Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Oramed Pharmaceuticals Inc (2008–2025)

The table below shows the annual Asset Resilience Ratio data for Oramed Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	34.63%	$79.95 Million	$230.86 Million	-21.73pp
2024-12-31	56.36%	$87.51 Million	$155.28 Million	-13.01pp
2023-12-31	69.37%	$152.99 Million	$220.55 Million	-1.94pp
2022-12-31	71.30%	$115.26 Million	$161.64 Million	+58.10pp
2021-12-31	13.20%	$16.89 Million	$128.00 Million	-32.96pp
2020-12-31	46.16%	$20.60 Million	$44.63 Million	-37.36pp
2019-12-31	83.53%	$28.95 Million	$34.66 Million	+29.80pp
2018-12-31	53.73%	$25.47 Million	$47.40 Million	+12.01pp
2017-12-31	41.73%	$16.15 Million	$38.71 Million	-21.57pp
2016-12-31	63.29%	$27.11 Million	$42.83 Million	+10.11pp
2015-12-31	53.18%	$14.02 Million	$26.35 Million	-36.39pp
2014-12-31	89.57%	$19.53 Million	$21.80 Million	+17.94pp
2013-12-31	71.63%	$6.20 Million	$8.66 Million	+67.84pp
2012-12-31	3.78%	$200.31K	$5.29 Million	-5.11pp
2011-12-31	8.89%	$384.56K	$4.33 Million	+2.00pp
2010-12-31	6.89%	$100.00K	$1.45 Million	-23.77pp
2009-12-31	30.66%	$1.00 Million	$3.26 Million	-18.88pp
2008-12-31	49.54%	$2.73 Million	$5.51 Million	--

pp = percentage points

About Oramed Pharmaceuticals Inc

NASDAQ:ORMP USA Biotechnology

Market Cap

$191.12 Million

Market Cap Rank

#17769 Global

#4191 in USA

Share Price

$4.67

Change (1 day)

+1.08%

52-Week Range

$2.19 - $5.34

All Time High

$29.75